Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: A culture-free analysis of gut microbiota

Clinical Microbiology and Infection

Volumn 21, Issue 4, 2015, Pages 344.e1-344.e11

  Stewardson, A J ^a,b   Gaia N ^a   Francois P ^a   Malhotra Kumar, S ^c   Delemont C ^a   Martinez de Tejada, B ^a   Schrenzel, J ^a   Harbarth, S ^a   Lazarevic, V ^a   Vervoort, J ^c   Lammens, C ^c   Adriaenssens, N ^c   Coenen, S ^c   Goossens, H ^c   Kowalczyk, A ^d   Godycki Cwirko, M ^d   Brossier, C ^a   Huttner, B ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Antibiotics; Ecologic damage; Microbiomics; Microbiota; Urinary tract infection

Indexed keywords

CIPROFLOXACIN; FOSFOMYCIN; NITROFURANTOIN; RNA 16S; ANTIINFECTIVE AGENT; BACTERIAL DNA; RIBOSOME DNA;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTEROIDES; BACTEROIDETES; BIFIDOBACTERIUM; CLOSTRIDIUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FAECALIBACTERIUM; FECES ANALYSIS; FEMALE; FIRMICUTES; HUMAN; INTESTINE FLORA; MALE; MICROBIAL COMMUNITY; PRIORITY JOURNAL; PYROSEQUENCING; URINARY TRACT INFECTION; BACTERIUM; CHEMISTRY; CLASSIFICATION; DNA SEQUENCE; DRUG EFFECTS; FECES; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; OUTPATIENT; PROSPECTIVE STUDY; URINARY TRACT INFECTIONS; YOUNG ADULT;

ACTINOBACTERIA; ALISTIPES; BACTERIA (MICROORGANISMS); BACTEROIDES; BACTEROIDETES; BIFIDOBACTERIUM; CLOSTRIDIUM; DIALISTER; FAECALIBACTERIUM; FIRMICUTES; OSCILLOSPIRA; ROSEBURIA; RUMINOCOCCUS;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIA; CIPROFLOXACIN; DNA, BACTERIAL; DNA, RIBOSOMAL; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; MALE; MIDDLE AGED; NITROFURANTOIN; OUTPATIENTS; PROSPECTIVE STUDIES; RNA, RIBOSOMAL, 16S; SEQUENCE ANALYSIS, DNA; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 84928571006     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.11.016     Document Type: Article

References (38)

1. Stewardson A.J., Huttner B., Harbarth S. At least it won't hurt: the personal risks of antibiotic exposure. Curr Opin Pharmacol 2011, 11:446-452.
2. Vollaard E.J., Clasener H.A. Colonization resistance. Antimicrob Agents Chemother 1994, 38:409-414.
3. Blaser M.J. Stop the killing of beneficial bacteria. Nature 2011, 476:393-394.
4. Pérez-Cobas A.E., Artacho A., Knecht H., Ferrús M.L., Friedrichs A., Ott S.J., et al. Differential effects of antibiotic therapy on the structure and function of human gut microbiota. PLoS One 2013, 8:e80201.
5. Mouton J.W., Ambrose P.G., Canton R., Drusano G.L., Harbarth S., MacGowan A., et al. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat 2011, 14:107-117.
6. Gupta K., Hooton T.M., Naber K.G., Wullt B., Colgan R., Miller L.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011, 52:e103-e120.
7. Dethlefsen L., Huse S., Sogin M.L., Relman D.A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008, 6:e280.
8. Dethlefsen L., Relman D.A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 2011, 108(Suppl.1):4554-4561.
9. Sullivan A., Edlund C., Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001, 1:101-114.
10. Klindworth A., Pruesse E., Schweer T., Peplies J., Quast C., Horn M., et al. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res 2013, 41:e1.
11. Schloss P.D., Westcott S.L., Ryabin T., Hall J.R., Hartmann M., Hollister E.B., et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 2009, 75:7537-7541.
12. McDonald D., Price M.N., Goodrich J., Nawrocki E.P., DeSantis T.Z., Probst A., et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J 2012, 6:610-618.
13. Lazarevic V., Gaïa N., Girard M., François P., Schrenzel J. Comparison of DNA extraction methods in analysis of salivary bacterial communities. PLoS One 2013, 8:e67699.
14. Altschul S.F., Gish W., Miller W., Myers E.W., Lipman D.J. Basic local alignment search tool. JMol Biol 1990, 215:403-410.
15. Bray J.R., Curtis J.T. An ordination of the upland forest communities of southern Wisconsin. Ecol Monogr 1957, 27:325-349.
16. Grayson M.L., Whitby M. Nitrofurans: nitrofurazone, furazolidone and nitrofurantoin. Kucers' the use of antibiotics 2010, Hodder Arnold/ASM Press, Washington, DC. 6th ed. M.L. Grayson (Ed.).
17. Sandegren L., Lindqvist A., Kahlmeter G., Andersson D.I. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. JAntimicrob Chemother 2008, 62:495-503.
18. Poulsen H.O., Johansson A., Granholm S., Kahlmeter G., Sundqvist M. High genetic diversity of nitrofurantoin- or mecillinam-resistant Escherichia coli indicates low propensity for clonal spread. JAntimicrob Chemother 2013, 68:1974-1977.
19. Pecquet S., Ravoire S., Andremont A. Faecal excretion of ciprofloxacin after a single oral dose and its effect on faecal bacteria in healthy volunteers. JAntimicrob Chemother 1990, 26:125-129.
20. Brismar B., Edlund C., Malmborg A.S., Nord C.E. Ciprofloxacin concentrations and impact of the colon microflora in patients undergoing colorectal surgery. Antimicrob Agents Chemother 1990, 34:481-483.
21. Frimodt-Moller N. Fosfomycin. Kucers' the use of antibiotics 2010, Hodder Arnold/ASM Press, Washington, DC. 6th ed. M.L. Grayson (Ed.).
22. Stamey T.A., Condy M., Mihara G. Prophylactic efficacy of nitrofurantoin macrocrystals and trimethoprim-sulfamethoxazole in urinary infections. Biologic effects on the vaginal and rectal flora. NEngl J Med 1977, 296:780-783.
23. Mavromanolakis E., Maraki S., Samonis G., Tselentis Y., Cranidis A. Effect of norfloxacin, trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections. JChemother 1997, 9:203-207.
24. O'Sullivan O., Coakley M., Lakshminarayanan B., Conde S., Claesson M.J., Cusack S., et al. Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy. JAntimicrob Chemother 2013, 68:214-221.
25. McOsker C.C., Fitzpatrick P.M. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. JAntimicrob Chemother 1994, 33(Suppl.A):23-30.
26. Ubeda C., Taur Y., Jenq R.R., Equinda M.J., Son T., Samstein M., et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. JClin Invest 2010, 120:4332-4341.
27. Khoruts A., Dicksved J., Jansson J.K., Sadowsky M.J. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. JClin Gastroenterol 2010, 44:354-360.
28. Sekirov I., Tam N.M., Jogova M., Robertson M.L., Li Y., Lupp C., et al. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. Infect Immun 2008, 76:4726-4736.
29. Derrien M., Vaughan E.E., Plugge C.M., de Vos W.M. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 2004, 54:1469-1476.
30. Dubourg G., Lagier J.C., Armougom F., Robert C., Audoly G., Papazian L., et al. High-level colonisation of the human gut by Verrucomicrobia following broad-spectrum antibiotic treatment. Int J Antimicrob Agents 2013, 41:149-155.
31. Lazarevic V., Manzano S., Gaïa N., Girard M., Whiteson K., Hibbs J., et al. Effects of amoxicillin treatment on the salivary microbiota in children with acute otitis media. Clin Microbiol Infect 2013, 19:E335-E342.
32. Mueller S., Saunier K., Hanisch C., Norin E., Alm L., Midtvedt T., et al. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol 2006, 72:1027-1033.
33. Kang S.S., Jeraldo P.R., Kurti A., Miller M.E., Cook M.D., Whitlock K., et al. Diet and exercise orthogonally alter the gut microbiome and reveal independent associations with anxiety and cognition. Mol Neurodegener 2014, 9:36.
34. Dubourg G., Lagier J.C., Robert C., Armougom F., Hugon P., Metidji S., et al. Culturomics and pyrosequencing evidence of the reduction in gut microbiota diversity in patients with broad-spectrum antibiotics. Int J Antimicrob Agents 2014, 44:117-124.
35. Lagier J.C., Armougom F., Million M., Hugon P., Pagnier I., Robert C., et al. Microbial culturomics: paradigm shift in the human gut microbiome study. Clin Microbiol Infect 2012, 18:1185-1193.
36. Gouba N., Raoult D., Drancourt M. Eukaryote culturomics of the gut reveals new species. PLoS One 2014, 9:e106994.
37. Greub G. Culturomics: a new approach to study the human microbiome. Clin Microbiol Infect 2012, 18:1157-1159.
38. Sokol H., Pigneur B., Watterlot L., Lakhdari O., Bermúdez-Humarán L.G., Gratadoux J.J., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008, 105:16731-16736.